SEARCH

SEARCH BY CITATION

References

  • 1
    Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 2229.
  • 2
    Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA 1998; 280: 7277.
  • 3
    Michelet C, Arvieux C, Francois C et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12: 18151822.
  • 4
    Lortholary O, Fontanet A, Mémain N et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19: 10431049.
  • 5
    Abgrall S, Rabaud C, Costagliola D, Clinical Epidemiology Group of the French Hospital Database of HIV. Incidence and risk factors for toxoplasmic encephalitis in human inmunodeficiency virus-infected patients before and during the highly active antirretroviral therapy era. Clin Infect Dis 2001; 33: 17471755.
  • 6
    UK Collaborative HIV Cohort (CHIC) Study Steering Committee, Garvey L, Winston A, Walsh J et al. HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol 2011; 18: 527534.
  • 7
    Shelburne SA, Hamill RJ, Rodriguez-Barradas MC et al. Immune reconstitution inflammatory syndrome. Emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002; 81: 213227.
  • 8
    French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 16151627.
  • 9
    Bicanic T, Meintjes G, Rebe K et al. Immune reconstitutions inflammatory syndrome in HIV-associated cryptococcal meningitis: a prostective study. J Acquir Immune Defic Syndr 2009; 51: 130134.
  • 10
    Torok ME, Kambugu A, Wright E. Immune reconstitution disease of the central nervous system. Curr Opin HIV AIDS 2008; 3: 438445.
  • 11
    Shelburne SA, Visnegarwala F, Darcourt J et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretrovirral therapy. AIDS 2005; 19: 399406.
  • 12
    Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answer, more questions. J Antimicrob Chemother 2006; 57: 167170.
  • 13
    Makadzange AT, Ndhlovy CE, Takarinda K et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in Sub-Saharan Africa. Clin Infect Dis 2010; 50: 15321538.
  • 14
    Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids. Neurology 2009; 72: 14581464.
  • 15
    Portegies P, Solod L, Cinque P et al. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol 2004; 11: 297304.
  • 16
    Mamidi A, DeSimone JA, Pomerantz RJ. Central nervous system infections in individuals with HIV-1 infection. J Neurovirol 2002; 8: 158167.
  • 17
    Falcó V, Olmo M, Del Saz SV et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observacional multicenter study. J Acquir Immune Defic Syndr 2008; 49: 2631.
  • 18
    Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 215261.
  • 19
    Johnson T, Nath A. Neurological complications of immune reconstitution in HIV-infected populations. Ann N Y Acad Sci 2010; 1184: 106120.
  • 20
    Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study investigators. N Engl J Med 1998; 338: 853860.
  • 21
    Sacktor N, Lyles RH, Skolasky R et al. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort study, 1990–1998. Neurology 2001; 56: 257260.
  • 22
    Kaplan JE, Hanson D, Dworkin MS et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30: S514.
  • 23
    Grabar S, Lanoy E, Allavena C et al. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008; 9: 246256.
  • 24
    Engsig FN, Hansen AB, Omland LH et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009; 199: 7783.
  • 25
    Cinque P, Pierotti C, Viganò MG et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7: 358363.
  • 26
    Antinori A, Cingolani A, Lorenzini P et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative NeuroAIDS (IRINA). J Neurovirol 2003; 9: 4753.
  • 27
    Cinque P, Bossolasco S, Brambilla AM et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurolovirol 2003; 9: 7380.
  • 28
    Albrecht H, Hoffmann C, Degen O et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998; 12: 11491154.
  • 29
    Khanna N, Elzi L, Mueller NJ et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV cohort study. Clin Infect Dis 2009; 48: 14591466.
  • 30
    Hall CD, Dafni U, Simpson D et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 1998; 338: 13451351.
  • 31
    Berenguer J, Miralles P, Arrizabalaga J et al. Clinical course and prognosis factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36: 10471052.
  • 32
    Wyen C, Hoffmann C, Schmeiβer N et al. Progressive multifocal leukoencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 2004; 37: 12631268.
  • 33
    Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O. The prevalence and risk of immune reconstitution restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005; 6: 140143.
  • 34
    Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42: 418427.
  • 35
    Murdoch DM, Venter WD, Feldman C, Van Die A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22: 601610.
  • 36
    Sungkanuparph S, Filler SG, Chetchotisakd P et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis 2009; 49: 931934.
  • 37
    Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatments options. AIDS Res Ther 2007; 8: 49.
  • 38
    Meintjes G, Rangaka MX, Maartens G et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009; 48: 667676.
  • 39
    Breton G, Duval X, Estellat C et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39: 17091712.
  • 40
    Shelburne SA 3rd, Darcourt J, Clinton White JA et al. The role of immune reconstitution inflammatory syndrome in AIDS-related cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 10491052.
  • 41
    Cooney EL. Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 224233.
  • 42
    Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007; 46: 456462.
  • 43
    Abdool Karim SS, Naidoo K, Grobler A et al. Timing of initiation of antiretroviral drugs during Tuberculosis therapy. N Engl J Med 2010; 362: 697706.
  • 44
    Castelnuovo B, Manabe YC, Kiragga A et al. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009; 49: 965972.